Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
May 16, 2024 06:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel and Beimei Pharma annouce an Asset Purcase Agreement to commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
Melinta Therapeutics Reports First Patient Treated in Phase 2 Study of Topical Radezolid for Treatment of Acne
November 13, 2017 07:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT) a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Newly Published Nonclinical Data Highlight the Role of Olumacostat Glasaretil in Sebum Inhibition
June 26, 2017 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., June 26, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Announces Appointment of Ian Clements as Vice President, Investor Relations
June 06, 2017 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., June 06, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira to Present at Jefferies 2017 Global Healthcare Conference
May 30, 2017 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., May 30, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Announces Closing of 3.00% Convertible Senior Notes Offering
May 16, 2017 16:01 ET
|
Dermira, Inc.
MENLO PARK, Calif., May 16, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today the closing of its previously announced offering of 3.00% Convertible Senior Notes due 2022 (the...
Dermira Prices Offering of $250 Million of 3.00% Convertible Senior Notes
May 10, 2017 21:32 ET
|
Dermira, Inc.
MENLO PARK, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today the pricing of its offering of $250,000,000 aggregate principal amount of 3.00% Convertible Senior...
Dermira Announces Proposed Offering of $250 Million of Convertible Senior Notes
May 09, 2017 16:01 ET
|
Dermira, Inc.
MENLO PARK, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today that it intends to offer, subject to market conditions and other factors, $250,000,000 aggregate...
Dermira Reports First Quarter 2017 Financial Results and Provides Corporate Update
May 08, 2017 16:08 ET
|
Dermira, Inc.
-Submissions for CIMZIA® (certolizumab pegol) and glycopyrronium tosylate remain on schedule for later this year MENLO PARK, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a...
Dermira to Present at Needham 16th Annual Healthcare Conference
March 28, 2017 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...